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Heavy-slow resistance training in addition
to an ultrasound-guided corticosteroid
injection for individuals with plantar
fasciopathy: a feasibility study
Henrik Riel1*, Jens Lykkegaard Olesen1, Martin Bach Jensen1, Bill Vicenzino2 and Michael Skovdal Rathleff1,3,4
Abstract
Introduction: Plantar fasciopathy, characterised by plantar heel pain, affects one in ten in a lifetime. Heavy-slow
resistance training (HSR) is an emerging treatment, but it often takes considerable time before the effect starts to
manifest. Combining HSR with a corticosteroid injection (known for its short-term pain relief) could potentially
improve outcomes in both short and long term. As this combination is yet to be investigated, we aimed to
evaluate the feasibility of combining HSR with a corticosteroid injection for individuals with plantar fasciopathy
before investigating the efficacy in a clinical trial.
Materials and methods: We recruited 20 participants with plantar fasciopathy for this prospectively registered
feasibility study (ClinicalTrials.gov: NCT03535896). Participants received an ultrasound-guided injection and
performed heel raises on a step every second day for 8 weeks. To assess participant acceptability of the combined
interventions and exercise compliance, we used a 7-point Likert scale dichotomised to “unacceptable” (categories
1–2) or “acceptable” (categories 3–7) and training diaries. Greater than or equal to 10/20 had to rate the
combination “acceptable”, ≥ 15/20 had to perform ≥ 20 training sessions, and ≥ 15/20 had to start exercising ≤ 7
days after injection to confirm feasibility.
Results: Eighteen out of 20 rated the combination acceptable. Five training diaries could not be retrieved. Ten out
of 15 participants performed ≥ 20 training sessions, and 15/15 started exercising ≤ 7 days after injection.
Conclusions: Based on participant acceptability and time to exercise start, combining HSR with corticosteroid
injection is feasible and the efficacy should be investigated in a future trial. Due to loss of 5/20 training diaries, firm
conclusions regarding exercise compliance could not be drawn.
Trial registration: ClinicalTrials.gov, NCT03535896
Keywords: Plantar fasciopathy, Corticosteroid injection, Heavy-slow resistance training, Acceptability, Compliance
Background
Plantar fasciopathy is a common musculoskeletal con-
dition and affects one in ten in a lifetime [1]. Pain is
often exacerbated during the first steps in the morn-
ing and after prolonged periods of non-weight bearing
[2]. Approximately half of patients referred to specia-
lised clinics may still experience pain 10 years after
treatment start [3]. Forty percent of patients still have
symptoms after 2 years despite having performed
plantar fascia-specific stretching and wearing insoles
[4]. Patients with plantar fasciopathy have been found
to show greater levels of depression, stress, anxiety,
and kinesiophobia and have limitations in both mobil-
ity and health-related quality of life compared with
sex- and age-matched healthy controls [5–7]. Plantar
fasciopathy is also associated with several days of sick
leave, and thus, plantar fasciopathy can have conse-
quences for both patient and society [8, 9].
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A recent systematic review and network meta-ana-
lysis compared the effect of several treatment options
for plantar fasciopathy. It concluded that no single
treatment was superior to others and that different
treatments may take different time to work [10]. A
corticosteroid injection has been found to be a safe
option for plantar fasciopathy and has a good short-
term effect compared with placebo, but there is no
added benefit after 1 month [11–13]. One treatment
option not included in the review was heavy-slow re-
sistance training (HSR). HSR is a frequently used
treatment option in the rehabilitation of both upper
and lower limb tendinopathies and has also been
found to be superior to stretching in plantar fasciopa-
thy, but its effects usually take several weeks to mani-
fest [14–17].
An injection and HSR could potentially supplement
each other and provide the patient with both the im-
mediate pain reduction associated with the injection
and the long-term pain reduction from performing
HSR. Repeated corticosteroid injections and a com-
bination of stretching and strengthening exercises
have been investigated before, but the combination of
HSR and a single corticosteroid injection is yet to be
investigated [18]. Due to the novelty of combining
these two treatments, the feasibility should be investi-
gated before investigating the treatment effect in a
larger-scale trial.
The purpose of this study is to investigate the feasibil-
ity of combining HSR with an ultrasound-guided cor-
ticosteroid injection to reduce pain in individuals with
plantar fasciopathy. Feasibility is evaluated using the ac-
ceptability of the combined treatments and exercise
compliance.
Methods
A cohort study design was implemented to follow pa-
tients with plantar fasciopathy over an 8-week period in
order to determine feasibility of combining an ultra-
sound-guided corticosteroid injection with an HSR
programme.
Study design and setting
This study was designed as an interventional feasibility
study. Reporting follows the items of the CONSORT 2010
statement: extension to randomised pilot and feasibility tri-
als that are applicable to a non-randomised design [19]. Be-
fore the inclusion of the first participant, the study was
registered on ClinicalTrials.gov (NCT03535896). All exami-
nations were conducted at the Research Unit for General
Practice in Aalborg, Denmark, by an experienced physio-
therapist. Injections were performed at a private rheumatol-
ogy clinic in Aalborg, Denmark, by a rheumatologist with
more than 15 years of experience with ultrasound-guided
injections. Data were collected using REDCap (Vanderbilt
University, Nashville, TN, USA). Baseline and the 8-week
follow-up were conducted at the study site whereas a link
to the questionnaires used was sent by REDCap to partici-
pants’ e-mail address for the 4-week follow-up.
Recruitment and eligibility criteria
Participants were recruited through social media (Face-
book) or from a local general practice. The primary in-
vestigator performed telephone screenings of potentially
eligible participants, and those who were not excluded
based on this screening were invited to a clinical exam-
ination where final eligibility was determined. Inclusion
criteria were as follows: (i) history of inferior heel pain
for at least 3 months before enrolment, (ii) pain on pal-
pation of the medial calcaneal tubercle or the proximal
plantar fascia, (iii) thickness of the plantar fascia of 4.0
mm or greater measured by ultrasound [20], and (iv)
mean heel pain ≥ 30mm on a 100-mm VAS during the
previous week. Exclusion criteria were as follows: (i)
below 18 years of age, (ii) diabetes, (iii) history of inflam-
matory systemic diseases, (iv) prior heel surgery, (v)
pregnancy or breastfeeding, (vi) corticosteroid injection
for plantar fasciopathy within the previous 6 months,
(vii) pain or stiffness in the first metatarsophalangeal
joint to an extent where the exercises could not be per-
formed, (viii) known hypersensitivity to corticosteroids
or local anaesthetics, or (ix) skin or soft tissue infection
near the injection site. These criteria were in line with
those of similar studies in this patient population and
had to be met by all participants [8, 11, 21].
Intervention
Patient advice
After eligibility was confirmed, participants received in-
formation regarding what is known about the condition
in terms of risk factors and aetiology, the pathology, and
the rationale for why the combination of HSR and an
ultrasound-guided corticosteroid injection could lead to
recovery. They were advised to decrease activities which
they felt caused symptom flare ups and slowly progress
their activity level guided by symptoms. They were also
informed about other types of evidence-based treat-
ments; however, they were asked to refrain from seeking
other treatments during the course of the study. Two
weeks after inclusion, the primary investigator contacted
participants to ask them if they had any questions re-
garding the condition or in relation to performing the
exercise.
Heavy-slow resistance training and heel cup
Participants were instructed in performing a heel raise
exercise standing with the forefoot on a step or a book
as per Rathleff et al. [17]. The toes should be maximally
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extended by placing a rolled towel underneath them.
Supporting themselves for balance by touching the
hands on a wall or a rail was allowed. Participants were
instructed to perform the exercise with a load as heavy
as possible, but no heavier than they would be able to
perform eight repetitions per set (i.e. eight repetition
maximum (RM)) and for as many sets as possible. This
self-dosed approach was found to be equal to the pre-
determined programme used by Rathleff et al. [21].
Further information about the exercise is displayed in
Table 1. If participants felt they were able to perform
more repetitions than their load corresponded to (e.g. 10
repetitions when the load was supposed to be 8RM), an
external load consisting of a backpack with books or
water bottles to add weight was used. We told partici-
pants that pain during the exercise was expected and
that there was no upper limit of pain they were allowed
to experience as long as they felt it was tolerable. Partici-
pants were asked to start performing the exercise as
soon as they felt ready but not before 24 h after the in-
jection. During the first 2 weeks after the injection, they
were asked not to progress the method used to achieve
8RM. If standing on both feet was sufficient to achieve
8RM at baseline, participants should not perform the
exercise single-legged until the third week after the in-
jection regardless of any pain reduction afforded by the
injection. They were, however, still asked to perform as
many sets as possible. Participants were told that com-
plying with the exercise programme was very important
and that exercise compliance was associated with their
recovery. To support the exercise execution, participants
received a training diary which included the exercise in-
struction and a link to a video in which the primary in-
vestigator showed the exercise instruction.
A silicone heel cup was given to all participants, and
they were advised to use the heel cup as much as pos-
sible. If participants already used an insole or any other
type of foot orthosis, they were allowed to continue
wearing this if they preferred it over the heel cup that
we provided.
Ultrasound-guided corticosteroid injection
Participants received an ultrasound-guided corticosteroid
injection between 5 and 8 days after baseline. A 21-gauge,
40-mm needle was connected to a 2.5-cm3 syringe filled
with 1ml triamcinolonhexacetonid (Lederspan, Meda A/
S, Allerød, Denmark) + 1ml lidocain 10mg/ml (Xylocain,
AstraZeneca A/S, Copenhagen, Denmark). The skin was
cleansed with chlorhexidine alcohol 0.5% (Medic, Meda
A/S, Allerød, Denmark). The needle was inserted with a
medial approach under ultrasound guidance aligned to
the long axis of the ultrasound transducer. The injection
was placed anterior to the plantar fascia insertion on the
calcaneal bone in the region of maximal fascia thickness.
Table 1 Mechano-biological descriptors
1. Load magnitude As heavy as possible, but no heavier than
a weight that can be lifted at least 8 times (8RM)
2. Number of repetitions ≥ 8 depending on the load
3. Number of sets As many as possible
4. Rest in between sets 2 min
5. Number of exercise interventions Performed every other day
6. Duration of the experimental period 8 weeks
7. Fractional and temporal distribution of
the contraction modes per repetition and
duration (s) of one repetition
3 s concentric
2 s isometric
3 s eccentric
8. Rest in-between repetitions No
9. Time under tension 8 s/repetition
≥ 64 s/set
≥ 64 s/training session
10. Volitional muscular failure Yes
11. Range of motion Full range of motion
12. Recovery time in-between
exercise sessions
48 h
13. Anatomical definition of
the exercise (exercise form)
The participant stands with the forefoot on a step.
The toes are maximally dorsal flexed by placing a
towel underneath them. The participant performs
a heel raise to maximal plantar flexion in the ankle
joint and afterwards lowers the heel to maximal
dorsal flexion. Supporting oneself for balance by
placing the hands on a wall or a rail is allowed.
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Outcomes
Feasibility outcomes
Before embarking upon a large randomised controlled
trial investigating the treatment effects, it is recom-
mended to investigate the feasibility including partici-
pant acceptability [22]. We chose three feasibility
outcomes: (i) Acceptability of the combined treatments
measured by a participant acceptability questionnaire
that included a 7-point Likert scale ranging from “very
unacceptable” to “very acceptable”. This was not a meas-
ure of whether participants’ symptoms had improved or
not, but if the treatment matched their expectations to
the content of the intervention and acceptability of per-
forming exercises after receiving an injection. This was
clearly stated in the questionnaire to emphasise that
changes in symptoms were not to be considered. The
combined treatments were categorised as “unacceptable”
if they were rated as “very unacceptable” or “unaccept-
able” (category 1–2) and categorised as “acceptable” if
they were rated from “slightly unacceptable” to “very ac-
ceptable” (category 3–7). We encouraged participants to
elaborate their response in a free-text field. The ques-
tionnaire was filled out during the 8-week follow-up. (ii)
Compliance to the exercises as measured by the mean
number of training sessions performed throughout the
intervention measured by a training diary that each par-
ticipant is handed out at baseline. The participants were
instructed in filling out the number of repetitions and
sets performed and the day on which they performed
the exercise. (iii) Mean days until participants started to
perform the exercise measured from after the injection.
Explorative outcomes
In addition to the feasibility outcomes, we collected the
following explorative outcomes to inform sample size
estimations for a future trial: (i) change in the domains
of the Danish version of the Foot Health Status Ques-
tionnaire (FHSQ) from baseline to the 4-week and 8-
week follow-ups [23]. The FHSQ is a self-report ques-
tionnaire ranging from 0 (poor foot health) to 100
(optimum foot health) that assesses multiple dimen-
sions of foot health and function and has a high reli-
ability (ICC = 0.74–0.92) [24]. The minimal important
differences of the domains are 14.1 points for pain, 7.4
points for function, and 9.2 points for general foot
health [25]. (ii) Change in mean daily heel pain mea-
sured on an 11-point Numerical Rating Scale (NRS)
(ranging from 0 which is no pain to 10 which is worst
pain imaginable) from before the injection to 1 week
after. This was chosen as an outcome to explore the
short-term effects of the injection. The minimal im-
portant difference of an 11-point NRS is 2 [26, 27]. Par-
ticipants received an SMS at the same timepoint every
day in which they were asked to rate their mean heel
pain during the past 24 h. The first SMS was sent the
day after baseline, and SMSs were sent until 1 week
after the injection. The SMS was sent using a smart-
phone (Huawei Y5, Huawei Technologies, Shenzhen,
China) and the application Do It Later (Go Vap Dst,
Ho Chi Minh City, Vietnam). (iii) Self-reported im-
provement measured on a 7-point Likert scale ranging
from “much improved” to “much worse” (the Global
Rating of Change (GROC)) at the 8-week follow-up.
Participants were categorised as improved if they rated
themselves as “much improved” or “improved” (cat-
egory 6–7) and categorised as not improved if they
rated themselves from “slightly improved” to “much
worse” (category 1–5) [28]. (iv) Change in plantar fascia
thickness from baseline to the 8-week follow-up mea-
sured in millimetres by ultrasonography. Measurements
were performed using a longitudinal scan with partici-
pants lying prone with the toes placed maximally ex-
tended on the examination table. An average of three
measurements was used (ICC = 0.67–0.77) [20]. (v)
Change in self-efficacy as measured by the Pain Self-Ef-
ficacy Questionnaire (PSEQ). The PSEQ ranges from 0
(not at all confident) to 60 (completely confident) with
lower scores indicating lower self-efficacy [29]. A vali-
dated Danish translation was used (ICC = 0.89) [30].
(vi) Change in physical activity level as measured by the
International Physical Activity Questionnaire short ver-
sion (IPAQ). The IPAQ estimates time spent perform-
ing vigorous and moderate activities, and time spent
walking during the past week measured in MET-mi-
nutes [31, 32]. (vii) Recruitment rate defined as the
mean number of participants recruited per week
throughout the recruitment period.
The FHSQ, PSEQ, and IPAQ were filled out during
baseline and at the 4-week and 8-week follow-ups
whereas the GROC was filled out during the 8-week fol-
low-up only. If participants were not categorised as im-
proved based on the GROC, they were offered a second
injection. If they accepted, they would receive the GROC
again after an additional 8 weeks of performing
exercises.
Sample size
Due to the nature of a feasibility study, a formal sample
size calculation was not performed [33, 34]. We aimed
to include 20 participants as we considered this an ad-
equate number to assess the feasibility of the combined
treatments.
Analyses
Feasibility
To conclude that the combined treatments were feasible,
we a priori decided during a consensus meeting that the
following three criteria would have to be met: (i) ≥ 10/20
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rated the combined treatments as “acceptable”. If any par-
ticipant dropped out after the injection, they would be
dichotomised as “unacceptable”. (ii) Based on the self-re-
ported training diaries, ≥ 15/20 participants would need to
have performed ≥ 20/28 possible training sessions, and
(iii) ≥ 15/20 participants would need to have started per-
forming the exercise ≤ 7 days after the injection.
Explorative
We used histograms and Q-Q plots to assess data nor-
mality. Due to the nature of a pilot study, no hypothesis
testing was performed and we report mean or median
changes over time and 95% confidence intervals or fre-
quency [19].
Results
Recruitment was started on May 31, 2018. Between June 8
and August 10, 2018, we included 20 participants. The
final day of data collection was October 11. Thirty-two
potential participants were either referred from general
practice or contacted the primary investigator directly. Of
these, 24 were eligible for the clinical examination. Four
were excluded; two individuals had a mean heel pain dur-
ing the past week < 30/100mm VAS, one individual was
breastfeeding, and one individual had a plantar fascia
thickness < 4mm. After the final participant had been in-
cluded, an additional 12 potential participants contacted
the primary investigator to be included. One participant
was lost to follow-up, and five training diaries could not
be retrieved. None of these participants appeared dissi-
milar at baseline to those who handed in the training
diary. Characteristics of the 20 included participants are
shown in Table 2. One participant experienced an adverse
event as she experienced pain in other areas of the foot
than the heel during HSR. Participants' previous care-
seeking behaviour is found in Additional file 1.
Feasibility results
The combined treatments were considered acceptable by
18/20 participants. According to the training diaries, 10/
15 participants performed ≥ 20 training sessions (mean
performed training sessions 20.8 (± 9.2)) and all started
performing the exercise ≤ 7 days after injection (mean
days 2.1 (± 1.1)).
Fifteen participants provided a reason for their re-
sponse to the question of acceptability. The most com-
mon theme that emerged was reduced pain afforded by
the injection when starting to perform the exercise (n =
3). Two participants thought that it was a good idea to
combine several treatments to hopefully increase the
odds of recovery. The one participant who evaluated the
combined treatments as not acceptable reasoned this
with increased pain in other parts of the foot than the
heel when performing the exercise. All comments are
found in Table 3.
Explorative results
Participants improved from baseline to 4 weeks in FHSQ
pain (mean change 15.8, 95% CI 3.0 to 28.6) and to the
8-week follow-up (mean change 13.5, 95% CI − 0.3 to
27.2). In the function domain of the FHSQ, participants
improved the scores more than the minimally important
difference of 7.4 points from both baseline to the 4-week
follow-up and to the 8-week follow-up (Table 4). Mean
daily heel pain decreased 1.2 NRS (95% CI 0.7 to 1.7)
from the days before (mean pain 5.5 (± 1.8) NRS) to 1
week after the injection (mean pain 4.3 (± 2.1) NRS)
(Fig. 1). According to GROC, 6/19 participants were im-
proved after the intervention. Four participants of those
who were not improved according to GROC agreed to
receive a second injection. One was dichotomised as im-
proved after the additional 8-week follow-up, and one
still had not improved. The remaining two were lost to
follow-up. We were actively recruiting participants for a
total of 6 weeks which led to a weekly recruitment rate
of 3.3 participants per week. The mean number of sets
performed per training session was 4.2 (± 2.4).
Discussion
Key results
This was the first study that included both HSR and an
ultrasound-guided corticosteroid injection in the treat-
ment of plantar fasciopathy. We found that 18/20 partic-
ipants rated the combined treatments acceptable, and
according to the 15 training diaries retrieved, they were
adequately complying with the exercise programme.
Interpretation of feasibility
Despite the efforts made to ensure that participants disre-
garded any changes of their symptoms in the evaluation of
acceptability, several of the comments (6/15) concerned
the treatment effect and differentiating between treatment
effect and acceptability of the content of treatments ap-
peared to be difficult. Even if only 6/19 participants
Table 2 Clinical and demographic baseline characteristics
Women (%) 16 (80)
Age (years) 51.7 (± 12.5)
Height (cm) 169.7 (± 8.9)
Mass (kg) 87.3 (± 16.3)
BMI (kg/m2) 30.3 (± 5.4)
Symptom duration (months)* 8 (6 to 11)
Pain during past week (/100 mm) 65.3 (± 13.3)
Bilateral pain (%) 6 (30)
Number of plantar fasciopathy episodes* 1 (1 to 3)
Data are presented as mean (SD) or count
*median (interquartile range)
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improved according to GROC, nearly all participants eval-
uated the combination of treatments as acceptable accord-
ing to dichotomisation which emphasises the acceptability
of combining both HSR and an injection.
Due to loss of training diaries, it is difficult to draw firm
conclusions regarding exercise compliance in our study.
Exercise compliance is considered a large challenge in the
rehabilitation of musculoskeletal conditions, and strategies
to increase compliance should be considered whenever
exercises are prescribed [35, 36]. Participants performed
approximately 75% of the training sessions prescribed
which may be interpreted as a high compliance [37]. To
increase compliance, we used training diaries and told pa-
tients that complying with the exercises was associated
with the odds of recovery, but additional strategies such as
phone calls or SMS reminders may be needed to increase
compliance even further in future trials [35].
Interpretation of explorative outcomes
This study was not powered to detect changes over time in
the explorative outcomes, and the results should be inter-
preted cautiously; however, several outcome measures
pointed in the same direction. Participants improved in
FHSQ pain, function, and footwear and in PSEQ from base-
line to the 4-week follow-up, but there was only a negligible
change from the 4-week to the 8-week follow-up. This is
similar to what was observed by both McMillan et al. and
Ball et al. following an ultrasound-guided corticosteroid in-
jection [11, 12]. Individuals with plantar fasciopathy who
perform HSR will usually experience a steady improvement
whereas those who are treated with a corticosteroid injec-
tion will experience a fast improvement with no further
benefit hereafter [11, 12, 17, 21]. While we did not compare
the combination to either of the individual interventions, the
trajectory of improvement in our study looks similar to what
Table 3 Participants’ reasons for their acceptability response. Translations were made as true to the original statement as possible
Original quote English translation
Det har været super fint at være smertefri i startet,
hvor jeg skulle påbegynde træning.
It has been super nice to be pain-free
from the start when I had to start the training.
Grunden til jeg er meget enig er fordi, den første
tid mærkede jeg ikke noget til smerterne pga.
Injektionen hvilket gjorde det nemmere at gennemføre
øvelserne og opgaverne i dagligdagen.
The reason why I very much agree is that from
the beginning I did not experience pain because
of the injection which made it easier to perform
the exercises and everyday tasks.
Hvis det har en effekt og injektionen sker
sjældent så finder jeg det acceptabelt
og en god måde at komme videre på. Det
er ikke just behageligt at få den, så vil
selfølgelig helst undgå det.
Men som sagt finder jeg det acceptabelt
når man tænker på for og imod.
If it has an effect and the injection happens rarely
then I find it acceptable and a good way of
moving on. It is not necessarily comfortable to get
it so I would, of course, rather avoid it. But, as I said,
I find it acceptable when you consider the pros and cons.
Stadig smerter og kraftløshed Still pain and debilitation
Virkningen af injektionen er udeblevet The effect of the injection failed to happen
Ukompliceret og nem behandling. Uncomplicated and easy treatment.
ikke mærket den store forskel,
efter de 2 første uge
Not felt any big change after the first 2 weeks
Kombinationen gav mening. Der
er enkelte gange gået mere end
to dage mellem træningen.
The combination made sense. A few times it
has been more than two days between the training.
Det værste var smerten i
forbindelse med injektionen
The worst was the pain in connection
with the injection
Meget fint med blot træning hver
2. dag, således ikke så tidskrævende.
Very nice with training just every two days
so not that time consuming.
Øvelserne har givet voldsomme
smerter andre steder i foden
The exercises have led to severe pains
in other parts of the foot
Træningen blev langt nemmere og
meget midre smertefyldt efter injektionen
med binyrebarkhomon
The training became much easier and less
painful after the injection with corticosteroid
Det kan siges acceptabel hvis der
er nogen effekt af indsprøjtningen
It can be called acceptable if there
is any effect of the injection
Om binyren har nogen effekt ved jeg
ikke, med det at man HAR fået en sprøjte
giver en vis “effekt” mentalt.
I do not know if the corticosteroid has any effect
but the fact that you HAVE received an injection
has somewhat of an “effect” mentally.
Godt med flere muligheder for behandling
på en gang. Så større chance for at det virker.
Nice with more treatment options at once.
So bigger chance for it to work.
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Table 4 Results of explorative outcomes
Mean (SD) Mean change (95% CI)
Baseline vs 4 weeks Baseline vs 8 weeks 4 weeks vs 8 weeks
FHSQ pain (0–100)
Baseline 41.1 (12.7) 15.8 (3.0 to 28.6) 13.5 (− 0.3 to 27.2) − 2.3 (− 12.2 to 7.6)
4 weeks 56.5 (26.6)
8 weeks 54.8 (28.2)
FHSQ function (0–100)
Baseline 61.9 (19.3) 11.8 (− 0.1 to 23.7) 12.9 (− 1.4 to 27.1) 1.0 (− 9.8 to 11.9)
4 weeks 71.9 (24.8)
8 weeks 74.3 (26.0)
FHSQ footwear (0–100)
Baseline 35.8 (21.8) 8.8 (− 5.0 to 22.6) 12.0 (− 0.4 to 24.5) 3.2 (− 2.6 to 9.1)
4 weeks 45.8 (29.0)
8 weeks 48.3 (27.6)
FHSQ general foot health (0–100)
Baseline 44.5 (21.0) − 6.3 (− 21.3 to 8.8) 9.0 (− 0.2 to 18.3) 15.3 (2.4 to 28.2)
4 weeks 35.1 (27.5)
8 weeks 50.9 (26.6)
PSEQ (0–60)
Baseline 42.1 (8.9) 5.2 (0.5 to 10.0) 5.8 (0.2 to 11.3) 0.6 (− 4.4 to 5.5)
4 weeks 47.0 (12.2)
8 weeks 48.2 (10.6)
Plantar fascia thickness (mm)
Baseline 5.6 (0.9) 0.3 (− 0.1 to 0.7)
8 weeks 5.3 (1.2)
Median (IQR) Median change (95% CI)
Baseline vs 4 weeks Baseline vs 8 weeks 4 weeks vs 8 weeks
IPAQ walk (MET)
Baseline 1155 (330–1732.5) − 132 (− 251 to 231) − 99 (− 921 to 317) − 1155 (− 1598 to − 330)
4 weeks 1386 (198–2079)
8 weeks 495 (297–1386)
IPAQ moderate (MET)
Baseline 540 (300–2220) 0 (− 1254 to 600) 0 (− 480 to 480) 600 (− 2104 to − 360)
4 weeks 720 (40–2880)
8 weeks 480 (240–960)
IPAQ vigorous (MET)
Baseline 440 (0–1520) 0 (− 480 to 480) 0 (− 73 to 313) − 400 (− 1107 to 0)
4 weeks 240 (0–1440)
8 weeks 240 (0–960)
IPAQ total (MET)
Baseline 2475.5 (1391–4614) 242 (− 922 to 2681) − 171 (− 1592 to 864) 423 (− 712 to 2084)
4 weeks 1935 (1200–6906)
8 weeks 2217 (1059–2772)
FHSQ Foot Health Status Questionnaire, PSEQ Pain Self-Efficacy Questionnaire, IPAQ International Physical Activity Questionnaire, MET metabolic equivalents
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has been observed in both lateral elbow tendinopathy and
gluteal tendinopathy where an injection may hamper the ef-
fect of exercises [15, 38]. We only followed participants for
8weeks as this was sufficient to allow for an evaluation of
acceptability, and thus, we cannot make any statement on
the long-term outcomes of combing HSR with a corticoster-
oid injection. Johannsen et al. [18] found a combination of
repeated injections and different exercises to be superior to
either exercises or injections alone. That study did not in-
clude follow-ups between baseline and the 3-month follow-
up, so it is not possible to compare our findings with theirs.
To our knowledge, this was the first study that investi-
gated the pain reduction following an ultrasound-guided
corticosteroid injection by collecting daily pain data from
the days before and after the injection was performed.
Contrary to common expectation, the injection did not
lead to a large pain reduction within a few days as the re-
duction of 1.2 NRS is approximately only half of the min-
imally important difference of NRS in chronic
musculoskeletal pain conditions [26, 27]. Clinicians who
use injections with corticosteroid for patients with plantar
fasciopathy may want to inform patients that they may
not experience a pain reduction within the first week.
Limitations
We believe our study has two limitations. Firstly, we were
not able to retrieve five training diaries and two of our feasi-
bility criteria were dependent on data from the diaries. As a
result, we cannot draw firm conclusions regarding exercise
compliance. In a future trial, additional emphasis should be
put on the importance of returning the training diaries
when they are handed to participants or other methods for
collecting exercise compliance such as SMSs or mobile ap-
plications may be used. Secondly, we did not want the exer-
cises to interfere with the measures of daily pain before the
injection, so we did not allow participants to start perform-
ing the exercise until after the injection. Therefore, some
participants did not start the exercise until 10 days after
they received the exercise instruction. To counteract this
limitation, participants received a written exercise instruc-
tion and a link to a video in which the primary investigator
showed the instruction.
Conclusions
Based on participant acceptability and time from partici-
pants received the injection to exercise start, combining
HSR with an ultrasound-guided corticosteroid injection
is feasible and the efficacy compared to other conserva-
tive treatments may be investigated in a randomised
trial. Due to loss of 5/20 training diaries, firm conclu-
sions regarding exercise compliance could not be drawn.
Additional file
Additional file 1: Online supplementary table of previous care-seeking
behaviour. (DOCX 16 kb)
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